TickerSpark Feed

XBI coverage

Every article, report, and earnings note where XBI appears.

The rate-cut trade is splitting in two: buy biotech, not every growth stock

A softer July PCE report could revive duration, but the best rebound candidates are profitable, catalyst-backed biotechs rather than every cash-burning growth stock. If inflation keeps yields high, JPM and Goldman offer the more defensible earnings-supported trade.

Aug 23, 2026·6 MIN

Biotech Interest Rates Valuation

On-Demand Research

Want a deeper dive on XBI?

Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.

Generate XBI Report

For Active Investors

Stock research for every investor

Reports on any stock
Daily market intelligence
AI analyst in your pocket
Portfolio analysis tools

Get Full Access →

Cancel anytime

Today's Top MoverHOOD

▲13.70%

Robinhood Markets, Inc. · $108.13

The rate-cut trade is splitting in two: buy biotech, not every growth stock

Want a deeper dive on XBI?

A new stock idea, every evening.

Stock research for every investor